|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **TABLE 1:** Overall descriptive statistics and bivariate analysis for patients surviving and expiring from aspergillosis by treatment type | | | | |
|  |  |  |  |
| Treatment† | Survived (%) | Expired (%) | P Value‡ |
| All patients | 168 (67.7) | 80 (32.3) | N/A |
| Mean age (SD) | 39.5 (22.4) | 42.8 (21.1) | .25 |
| Mean number of agents (SD) | 2.3 (1.2) | 1.9 (1.0) | .06 |
|  |  |  |  |
| **Surgery** |  |  |  |
| No | 89 (61.0) | 57 (39.0) | <.05 |
| Yes | 79 (77.5) | 23 (22.5) |
|  |  |  |  |
| **Intrathecal** |  |  |  |
| None | 151 (66.2) | 77 (33.8) | .09 |
| AmpB | 13 (81.2) | 3 (18.8) | .23 |
| VCZ | 1 ( 100.0) | 0 (0.0) | .49 |
| L AmpB | 2 (100.0) | 0 (0.0) | .33 |
|  |  |  |  |
| **Systemic** |  |  |  |
| VCZ | 112 (78.3) | 31 (21.7) | <.001 |
| Capsofungin | 21 (61.8) | 13 (38.2) | .42 |
| AmpB | 66 (61.1) | 42 (38.9) | .05 |
| L AmpB | 62 (75.6) | 20 (24.4) | .06 |
| ABLC | 2 (66.7) | 1 (33.3) | .97 |
| ABCD | 1 (100.0) | 0 (0.0) | .49 |
| ITZ | 48 (82.8) | 10 (17.2) | <.05 |
| Isa-vuconazole | 1 (100.0) | 0 (0.0) | .49 |
| Posaconazole | 4 (57.1) | 3 (42.9) | .54 |
| 5FC | 12 (66.7) | 6 (33.3) | .92 |
| Fluconazole | 13 (50.0) | 13 (50.0) | <.05 |
|  |  |  |  |
| †Data only shown for those patients receiving the listed treatment option.  ‡Statistical analysis performed in R Studio using Chi-squared testing for categorical variables and Student’s t-test for continuous variables to determine difference between survival base on treatment type. Significance determined at the p < .05 level. Those variables reaching significance on bivariate analysis were included in the subsequent regression analysis. | | | | |